Correlation Between Virtus LifeSci and Loncar Cancer

Can any of the company-specific risk be diversified away by investing in both Virtus LifeSci and Loncar Cancer at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virtus LifeSci and Loncar Cancer into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virtus LifeSci Biotech and Loncar Cancer Immunotherapy, you can compare the effects of market volatilities on Virtus LifeSci and Loncar Cancer and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virtus LifeSci with a short position of Loncar Cancer. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virtus LifeSci and Loncar Cancer.

Diversification Opportunities for Virtus LifeSci and Loncar Cancer

0.89

Correlation Coefficient

Virtus LifeSci  Loncar Cancer

Very poor diversification

The 3 months correlation between Virtus and Loncar is 0.89. Overlapping area represents the amount of risk that can be diversified away by holding Virtus LifeSci Biotech and Loncar Cancer Immunotherapy in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Loncar Cancer Immuno and Virtus LifeSci is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virtus LifeSci Biotech are associated (or correlated) with Loncar Cancer. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Loncar Cancer Immuno has no effect on the direction of Virtus LifeSci i.e., Virtus LifeSci and Loncar Cancer go up and down completely randomly.

Pair Corralation between Virtus LifeSci and Loncar Cancer

Considering the 90-day investment horizon Virtus LifeSci Biotech is expected to under-perform the Loncar Cancer. In addition to that, Virtus LifeSci is 1.04 times more volatile than Loncar Cancer Immunotherapy. It trades about -0.15 of its total potential returns per unit of risk. Loncar Cancer Immunotherapy is currently generating about -0.13 per unit of volatility. If you would invest  1,217  in Loncar Cancer Immunotherapy on December 28, 2024 and sell it today you would lose (213.00) from holding Loncar Cancer Immunotherapy or give up 17.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Virtus LifeSci Biotech  vs.  Loncar Cancer Immunotherapy

Virtus LifeSci Biotech

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virtus LifeSci Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's fundamental drivers remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders.

Loncar Cancer Immuno

Risk-Adjusted Performance

Very Weak

Over the last 90 days Loncar Cancer Immunotherapy has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Etf's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the ETF retail investors.

Pair Trading with Virtus LifeSci and Loncar Cancer

The main advantage of trading using opposite Virtus LifeSci and Loncar Cancer positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virtus LifeSci position performs unexpectedly, Loncar Cancer can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will offset losses from the drop in Loncar Cancer's long position.

The idea behind Virtus LifeSci Biotech and Loncar Cancer Immunotherapy pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.